Merck & Co., Inc.

MRK

US58933Y1055

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 01:33:38 2024-07-17 pm EDT			5-day change	1st Jan Change
125.9 ^USD	+0.37%		-1.15%	+15.42%

04:18pm	Stocks to watch as Biden, Trump vie for presidency	RE
03:32pm	TD Cowen Adjusts Price Target on Merck to $140 From $135	MT

Variational AI Announces Generative AI Project With Merck

January 25, 2024 at 07:00 am EST

Variational AI announced a project with Merck Research Labs supported by the CQDM Quantum Leap program. The collaboration is supported by CQDM under the Quantum Leap program.

Latest news about Merck & Co., Inc.

Stocks to watch as Biden, Trump vie for presidency	10:18am	RE
TD Cowen Adjusts Price Target on Merck to $140 From $135	09:32am	MT
Merck: to present its advances in HIV at AIDS 24	Jul. 16	CF
Goldman Sachs Adjusts Price Target on Merck & Company to $145 From $144	Jul. 16	MT
Novo owner backs Swiss biotech Asceneuron in $100 million round	Jul. 16	RE
Sector Update: Health Care Stocks Mixed Premarket Friday	Jul. 12	MT
Sector Update: Health Care	Jul. 12	MT
Merck: completes acquisition of EyeBio	Jul. 12	CF
Merck Completes Eyebiotech Acquisition	Jul. 12	MT
Immutep Achieves 'Positive' Results From Cohort B of Phase 2B Cancer Trial; Shares Rise Pre-Bell	Jul. 12	MT
Merck & Co., Inc. completed the acquisition of Eyebiotech Limited.	Jul. 11	CI
Morgan Stanley Adjusts Price Target on Merck to $134 From $132	Jul. 11	MT
Merck: acquires aquatics division of Elanco Animal Health	Jul. 09	CF
Merck's Animal Health Division Completes $1.3 Billion Acquisition of Elanco Animal Health's Aqua Business	Jul. 09	MT
Prelude Therapeutics Inks Deal With Merck for Phase 2 Study to Evaluate its SMARCA2 Degrader With Keytruda	Jul. 09	MT
Stocks to watch as Biden and Trump vie for presidency	Jul. 03	RE
Merck, Orion Convert Ongoing Collaboration Into Exclusive Global License for Opevesostat	Jul. 01	MT
Merck: license agreement with Orion Corp. for opevesostat	Jul. 01	CF
Merck, Orion Convert Collaboration Into Exclusive License	Jul. 01	DJ
Orion Corporation and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat	Jul. 01	CI
Merck & Co., Inc.(NYSE:MRK) dropped from Russell Top 200 Value Index	Jun. 30	CI
Merck & Co., Inc.(NYSE:MRK) added to Russell 1000 Dynamic Index	Jun. 30	CI
Merck & Co., Inc.(NYSE:MRK) dropped from Russell 3000 Value Index	Jun. 30	CI
Merck & Co., Inc.(NYSE:MRK) dropped from Russell 1000 Value-Defensive Index	Jun. 30	CI
Merck & Co., Inc.(NYSE:MRK) dropped from Russell 1000 Value Index	Jun. 30	CI

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (18%); - sale of animal health products (9.4%); - other (2.9%). Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).

Sector

Pharmaceuticals

Calendar

2024-07-23 - International AIDS Conference

Related indices

Dow Jones Industrial , S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Merck & Co., Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

125.4 USD

Average target price

142.9 USD

Spread / Average Target

+13.92%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MERCK & CO., INC.	+15.42%	318B
ELI LILLY AND COMPANY	+56.95%	848B
NOVO NORDISK A/S	+31.64%	627B
JOHNSON & JOHNSON	-0.06%	363B
ABBVIE INC.	+12.50%	299B
ASTRAZENECA PLC	+15.51%	243B
NOVARTIS AG	+16.72%	225B
AMGEN INC.	+16.32%	179B
PFIZER, INC.	+3.32%	167B
SANOFI	+2.52%	125B

Other Pharmaceuticals

Merck & Co., Inc.

Equities

MRK

US58933Y1055

Pharmaceuticals

Variational AI Announces Generative AI Project With Merck

Latest news about Merck & Co., Inc.

Chart Merck & Co., Inc.

Company Profile

Income Statement Evolution

Ratings for Merck & Co., Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals